The 仁川经济自由区厅, 翰林制药, and 仁川科技园 (ITP) signed a business agreement on the 22nd to discover and nurture 初创企业s in the bio sector.
Under this agreement, the institutions plan to identify 初创企业s with technologies demanded by the industry and support product validation and commercialization.
翰林制药 is a leading company specializing in hypertension, osteoporosis, and 眼科 制药s, ranking first domestically in 眼科 制药 production capacity.
In June of last year, the company registered as an accelerator (初创企业 planner) to focus on investing in and nurturing bio 初创企业s and promoting co-growth, participating in 联合研发 for global 制药 development as a strategic investor (SI).
In particular, after signing an investment agreement worth KRW 15 billion with 仁川创业园区 resident company RudaCure Inc., 翰林制药 has been actively supporting the development of RCI001, the 干眼症治疗药.